Prestige Consumer Healthcare's (PBH) "Neutral" Rating Reaffirmed at DA Davidson

DA Davidson reissued their neutral rating on shares of Prestige Consumer Healthcare (NYSE:PBH - Free Report) in a report issued on Thursday, Benzinga reports. The brokerage currently has a $65.00 price objective on the stock.

Several other equities analysts have also issued reports on PBH. TheStreet upgraded Prestige Consumer Healthcare from a c+ rating to a b- rating in a research report on Monday, February 12th. StockNews.com raised shares of Prestige Consumer Healthcare from a buy rating to a strong-buy rating in a research report on Monday. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of Moderate Buy and a consensus target price of $95.00.

Prestige Consumer Healthcare Trading Down 2.2 %

NYSE:PBH traded down $1.48 on Thursday, hitting $64.98. 534,647 shares of the stock were exchanged, compared to its average volume of 242,185. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of -39.62, a P/E/G ratio of 1.91 and a beta of 0.53. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.92 and a current ratio of 3.09. Prestige Consumer Healthcare has a 52 week low of $55.96 and a 52 week high of $75.31. The company's 50-day moving average price is $71.02 and its 200 day moving average price is $65.19.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Tuesday, May 14th. The company reported $1.02 earnings per share for the quarter, missing analysts' consensus estimates of $1.14 by ($0.12). Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The business had revenue of $277.00 million for the quarter, compared to the consensus estimate of $287.42 million. During the same period last year, the firm earned $1.07 earnings per share. The company's quarterly revenue was down 3.1% on a year-over-year basis. On average, equities research analysts forecast that Prestige Consumer Healthcare will post 4.33 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds have recently bought and sold shares of PBH. GAMMA Investing LLC bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $25,000. Provence Wealth Management Group bought a new position in Prestige Consumer Healthcare during the 3rd quarter worth about $26,000. Pacer Advisors Inc. increased its holdings in Prestige Consumer Healthcare by 85.7% during the 4th quarter. Pacer Advisors Inc. now owns 442 shares of the company's stock worth $27,000 after purchasing an additional 204 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $29,000. Finally, ORG Partners LLC bought a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $36,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.